SCA
ENZ

Snowden Capital Advisors’s Enzo Biochem, Inc. ENZ Stock Holding History

Snowden Capital Advisors’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,245
Closed -$11.5K – 1273
2024
Q3 		$11.5K Sell
10,245
-1,800
-15% -$2.01K ﹤0.01% 1211
2024
Q2 		$13.1K Sell
12,045
-8,400
-41% -$9.46K ﹤0.01% 1181
2024
Q1 		$26K Hold
20,445
– – ﹤0.01% 1163
2023
Q4 		$28.4K Sell
20,445
-1,054
-5% -$1.4K ﹤0.01% 1106
2023
Q3 		$30.1K Sell
21,499
-1,200
-5% -$1.81K ﹤0.01% 1046
2023
Q2 		$41.8K Buy
22,699
+200
+0.9% +$463 ﹤0.01% 1158
2023
Q1 		$54.7K Sell
22,499
-6,605
-23% -$9.82K ﹤0.01% 1125
2022
Q4 		$41.6K Sell
29,104
-2,600
-8% -$5.07K ﹤0.01% 1111
2022
Q3 		$70K Sell
31,704
-1,350
-4% -$3.26K ﹤0.01% 1083
2022
Q2 		$68K Sell
33,054
-3,000
-8% -$7.42K ﹤0.01% 1086
2022
Q1 		$104K Buy
36,054
+6,405
+22% +$20.6K ﹤0.01% 993
2021
Q4 		$95K Sell
29,649
-1,500
-5% -$5.12K ﹤0.01% 859
2021
Q3 		$110K Sell
31,149
-300
-1% -$1K 0.01% 856
2021
Q2 		$99.7K Sell
31,449
-400
-1% -$1.26K 0.01% 863
2021
Q1 		$110K Buy
31,849
+850
+3% +$2.64K 0.01% 785
2020
Q4 		$78.1K Buy
30,999
+1,600
+5% +$3.48K 0.01% 663
2020
Q3 		$62K Buy
29,399
+1,600
+6% +$3.8K 0.01% 568
2020
Q2 		$62.3K Buy
27,799
+4,349
+19% +$11.2K 0.01% 546
2020
Q1 		$59.3K Buy
23,450
+3,800
+19% +$9.34K 0.01% 512
2019
Q4 		$51.7K Sell
19,650
-409
-2% -$1.22K ﹤0.01% 578
2019
Q3 		$72.2K Buy
20,059
+2,000
+11% +$7.08K 0.01% 507
2019
Q2 		$60.9K Buy
18,059
+1,650
+10% +$5.81K 0.01% 505
2019
Q1 		$44.8K Buy
16,409
+2,600
+19% +$8.51K ﹤0.01% 491
2018
Q4 		$38.4K Buy
13,809
+3,700
+37% +$12.1K 0.01% 464
2018
Q3 		$41.6K Buy
+10,109
New +$45.9K ﹤0.01% 487

Other funds holding ENZ

HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Snowden Capital Advisors's ENZ Position: Q4 2024 in Review

Snowden Capital Advisors sold out of Enzo Biochem, Inc. (ENZ) in Q4 2024, closing a stake of 10,245 shares — an estimated $11.5K sold.

Snowden Capital Advisors first reported a position in ENZ in Q3 2018 and held it in 25 quarters. The position peaked at $110K in Q3 2021. 45 funds tracked by Wall St. Rank hold ENZ as of Q4 2024.

  • Snowden Capital Advisors reported no remaining Enzo Biochem, Inc. position as of Q4 2024 after selling out during the quarter.
  • Snowden Capital Advisors sold 10,245 Enzo Biochem, Inc. shares in Q4 2024, an estimated $11.5K.
  • Snowden Capital Advisors first reported a position in Enzo Biochem, Inc. in Q3 2018 and held it in 25 quarters.
  • Snowden Capital Advisors's Enzo Biochem, Inc. position peaked at $110K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2024.

Based on Snowden Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.